{"preliminary_commentary":{"by_channel":{"x_thread":47,"podcast":31,"youtube":29,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05048797\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DESTINY-Lung04","nct_id":"NCT05048797","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-lung04-nct05048797. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Trastuzumab Deruxtecan (T-DXd)","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-07-30","type":"ESTIMATED"},"conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":454,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab Deruxtecan","otherNames":["DS-8201a; T-DXd"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"AstraZeneca","official_title":"An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)","timeFrame":"Until progression or death, assessed up to approximately 12 months"}],"references":[],"start_date":{"date":"2021-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","url":"https://clinicaltrials.gov/study/NCT05048797"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-lung04-nct05048797"}